Chester County News and Community Website
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The …
Read More
HARRISBURG, PA — The Pennsylvania Department of Health recently released a report on COVID-19 post-vaccination events, commonly known as “breakthrough,” showing that the vaccines continue to save lives and keep …
Read More
FORT WASHINGTON, PA — Nabriva Therapeutics plc (NASDAQ: NBRV) recently published the first data to demonstrate the anti-inflammatory activity of XENLETA® (lefamulin).
Read More
HARRISBURG, PA — Governor Tom Wolf this week sent a letter to the General Assembly announcing the availability of COVID-19 vaccination rates by legislative district on the commonwealth’s open data portal, in addition …
Read More
CHEYNEY, PA — Navrogen Inc. and Tavotek Biotherapeutics announced today that they have entered into a strategic collaboration to identify and develop experimental monoclonal antibodies (mAbs) for the treatment of …
Read More
WASHINGTON, D.C. — The Centers for Disease Control and Prevention has shared a study, of COVID-19 infections in Kentucky among people who were previously infected with SAR-CoV-2, which shows unvaccinated …
Read More
HATFIELD, PA — AllerGenis, a predictive data analytics company specializing in the detection and management of life-threatening immune response disorders including food allergy, announced the publication of a peer-reviewed study entitled, “Accurate …
Read More HATFIELD, PA — AllerGenis, a predictive data analytics company specializing in the detection and management of life-threatening immune response disorders initially focused on food allergy, announced that the company’s chief scientific …
Read More
WASHINGTON, D.C. — The following quote is attributed to Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices …
Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or …
Read More